Clinical Trial Update: PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing PAR-101/OPT-80 with vancomycin for Clostridioides difficile infection (CDI) and associated diarrhea has completed with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• PAR-101/OPT-80
• Vancomycin (vancomycin)

Snippet

Sponsor: Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Clostridium Infections, Diarrhea | Phase 3 | Status: COMPLETED | Results posted: 2011-07-29